GBT - Global Blood Th Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-0.35%) NFLX (-0.17%) ETHUSD (%) UGAZ (-10.68%) LEVI (-1.6%) KAR (0.57%) IMRN (46.76%) GOOG (0.29%) FCG (-2.34%) FAST (1.96%) EBAY (-0.87%) DISCA (0.59%) DIS (-0.53%) CXW (-2.57%) CRZO (4.58%) CODX (6.39%) CMCSA (0.83%) CHWY (-0.85%) CEI (-11.03%) CDEV (-4.36%) CAPR (-3.7%) BTCUSD (%) BOOM (0.39%) BATUSD (%) AMZN (-0.55%)

GBT - Global Blood Therape...

$55.66 -2.25[-3.89%]

15 mins delayed data

People also watch : OPHLY | ONCX | OMER

+Watchlist

3 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$57.91	Open	$58.15
Volume	632.7K	Market Cap	3.502B
Yield		Last Dividend

Day

52 Week

Should You Pick Up Novartis (NVS) Before...	3:05 PM
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of Ap...

Novartis' (NVS) Crizanlizumab Gets P...	7:07 AM
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell d...

GBT and Advocates Launch Disease Awarene...	07/10/19
Global Blood Therapeutics, Inc. (GBT) (GBT), in partnership with sickle cell community-based organizations (CBOs), today announced the launch of Sickl...

GBT Announces New Employment Inducement ...	07/09/19
SOUTH SAN FRANCISCO, Calif., July 09, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2019, the compensati...

Local researcher part of 'exciting&#...	07/05/19
Currently, there are only two Food & Drug Administration treatments that are approved for sale and use in the U.S.

ANALYST RATINGS

4 analyst ratings (Last 6 months)

50.00 %

Strong Buy + Buy

Price Target (PT)

Hold rating	05/29/19
and announces Price Target of $75.00

Strong Buy rating	04/01/19
Wells Fargo maintains Outperform rating and raises Price Target from $85.00 to $96.00

Strong Buy rating	03/05/19
Wedbush maintains Outperform rating and raises Price Target from $91.00 to $95.00

Hold rating	03/04/19
Morgan Stanley maintains Equal-Weight rating and raises Price Target from $55.00 to $57.00

EARNINGS

Date	2019-05-08 (AMC)	Est. (EPS/Rev.)	($0.94)/ 0
Actual (EPS/Rev.)	$-0.87/	EPS (TTM)	0

TRADERS TRACKING $GBT

Service Name	Trader	% Success
Trading	Trading	99.00 %	Follow
Biotechnology	Robert Gadimian	26.00 %	Follow
Nonstop Trades	SECH DURMAZ	25.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.

Total Revenue	$1.3B	Total Liabilities	$2.1B
Cost of Revenue	$2.5B	Total cash flow	$3.2
Total Assets	$29.98B

Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%